GS
ACAD icon

GTS Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

GTS Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-74,400
Closed -$1.38M – 3879
2024
Q1 		$1.38M Buy
74,400
+28,300
+61% +$701K ﹤0.01% 1740
2023
Q4 		$1.44M Buy
46,100
+6,500
+16% +$155K ﹤0.01% 1894
2023
Q3 		$825K Buy
+39,600
New +$1.08M ﹤0.01% 2167

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GTS Securities's ACAD Position: Q4 2024 in Review

GTS Securities sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 14,712 shares — an estimated $226K sold.

GTS Securities first reported a position in ACAD in Q3 2023 and held it in 5 quarters. The position peaked at $1.22M in Q3 2023. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • GTS Securities reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 14,712 Acadia Pharmaceuticals shares in Q4 2024, an estimated $226K.
  • GTS Securities first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • GTS Securities's Acadia Pharmaceuticals position peaked at $1.22M in Q3 2023.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.